| Literature DB >> 32667245 |
Romy Barthel1,2,3, Oleg Fedorchenko1,2,3, Tanja Velmans1,2,3, Natascha Rosen1,2,3, Phuong-Hien Nguyen1,2,3, Nina Reinart1,2,3, Alexandra Florin4, Marco Herling1,2,3, Michael Hallek1,2,3, Günter Fingerle-Rowson1,2,3.
Abstract
CD74 is a surface protein expressed on immune cells, which acts as receptor for the chemokine macrophage migration inhibitory factor (MIF). Signaling via the MIF/CD74-axis has been reported to be important for the pathogenesis of chronic lymphocytic leukemia (CLL). We wanted to clarify the role of CD74 in MIF-induced signaling/leukemic development. In Eμ-TCL1 transgenic mice, occurrence of the leukemic phenotype was associated with increased surface CD74 expression. Eμ-TCL1+/+Cd74-/- mice showed similar kinetics and clinical features of CLL development as Eμ-TCL1+/+ mice. MIF stimulation of leukemic splenocytes led to AKT activation in a CD74-dependent manner. AKT activation was reduced in Cd74-deficient splenocytes in the presence of the oncogenic TCL1-transgene. Tumor cell apoptosis/proliferation were unaffected in Eμ-TCL1+/+Cd74-/- mice. Our data suggest that the need for active CD74 signaling is overcome in the leukemic context of TCL1-driven CLL, and that CD74 may have a dispensable role for CLL pathogenesis in this model.Entities:
Keywords: B-cells; CD74; CLL; MIF; TCL1
Mesh:
Substances:
Year: 2020 PMID: 32667245 DOI: 10.1080/10428194.2020.1791851
Source DB: PubMed Journal: Leuk Lymphoma ISSN: 1026-8022